Equity Profile

IRON

Disc Medicine, Inc.

Health CareBiotechnology$2.6B

May5Tue

Post-Earnings Recap

ReportedQ1-2026Pre-Market8:30 AM EDT

Disc Medicine, Inc. Misses on EPS, Stock Down 0.07%

Metric	Actual	Expected	Surprise
EPS	$-1.65	$-1.73	+6.45%
Revenue	$0M	$0M	—

management commentary, guidance changes, and full analysis available with Pro.

Disc Medicine, Inc. Misses on EPS, Stock Down 0.07%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-1.65	$-1.73	+6.45%
Revenue	$0M	$0M	—

Management Commentary

Tone: Unknown

No transcript is on record for the earnings call, so the analysis is based solely on numerical results.

What It Means

Disc Medicine reported a narrower loss per share than expected, which is a positive sign for investors. However, the lack of revenue and guidance may raise concerns about future performance. The stock reacted slightly down by 0.07%, indicating that investors are cautious following the earnings report.

Company Snapshot

Disc Medicine, Inc. is a biotechnology company focused on developing innovative therapies for patients with rare blood disorders....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability, and investors will be looking for any signs of improvement or worsening losses.

-1.73

Revenue

Although no revenue is expected this quarter, any revenue generated would signal progress in the company's product development.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Disc Medicine, Inc. is a biotechnology company focused on developing innovative therapies for patients with rare blood disorders. Operating in the health care sector, the company aims to address significant unmet medical needs, which is crucial as the demand for specialized treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-39.84%

Avg Stock Reaction

+0.34%

Last Quarter Recap

In Q4-2025, Disc Medicine reported a significant EPS loss of $-6.01, which was much worse than the expected loss of $-1.69. The stock reacted positively the next day, gaining 1.52%.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect another challenging quarter for Disc Medicine, with a consensus EPS loss of $-1.73. The company has not provided specific guidance, leading to uncertainty among investors.

Bull Case

If the company can narrow its losses and provide positive updates on its product pipeline, it could signal a turnaround, attracting investor interest.

Bear Case

Continued larger-than-expected losses could raise concerns about the company's financial health and ability to fund its operations.

Key Metrics to Watch

EPS

-1.73

Earnings per share is a key indicator of profitability, and investors will be looking for any signs of improvement or worsening losses.

Revenue

$0M

Although no revenue is expected this quarter, any revenue generated would signal progress in the company's product development.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS loss be closer to the consensus estimate of $-1.73 or worse?

The market will closely watch the EPS figure as it reflects the company's financial health and operational efficiency.

Is there any revenue generated this quarter?

Any revenue would indicate progress in the company's product development and could positively influence investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a narrower EPS loss this quarter, as recent operational adjustments could lead to improved cost management.

Supporting Evidence

The historical trend shows that the company has occasionally beaten EPS estimates despite a difficult environment.

Options pricing suggests a higher expected move than historical averages, indicating that traders may anticipate a surprise.

Key Risk

If the EPS loss comes in better than $-1.55, it could challenge the current negative sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will provide insights into the company's ability to manage costs and develop its product pipeline.

Bull Confirmed If

An EPS loss of $-1.55 or better would confirm the bull case, suggesting improved financial performance.

Bear Confirmed If

An EPS loss of $-2.07 or worse would confirm the bear case, raising concerns about the company's sustainability.

Pre-Earnings Positioning

Options Market

Implied Move

±8.27%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±8.3% while IRON has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

33.2%

Calls (0)P/C Ratio: 2.50Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 4 of 18 (22%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 18 (78%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 6.8%, with a raw directional average of +3.0% (modestly positive historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$841,283.01

12,388 sh

2 insiders

Net

$841,283.01

Net selling

Most Active Insiders· 4 open-market trades

Chief Financial OfficerFranchi Jean M.
$460,834.05

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Disc Medicine beats expectations with a smaller EPS loss, history suggests the stock could rise by around 0.08%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

A larger-than-expected EPS loss could lead to a decline of about 0.79%, reflecting ongoing concerns about the company's financial stability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product development timelines and potential revenue generation.
2Management's commentary on cost management strategies and operational efficiency.
3Insights into the company's cash runway and funding strategies.
4Any changes in the competitive landscape that could impact the company's market position.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Disc Medicine, Inc. is a biotechnology company focused on developing innovative therapies for patients with rare blood disorders....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability, and investors will be looking for any signs of improvement or worsening losses.

-1.73

Revenue

Although no revenue is expected this quarter, any revenue generated would signal progress in the company's product development.

$0M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-39.84%

Avg Stock Reaction

+0.34%

Last Quarter Recap

In Q4-2025, Disc Medicine reported a significant EPS loss of $-6.01, which was much worse than the expected loss of $-1.69. The stock reacted positively the next day, gaining 1.52%.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect another challenging quarter for Disc Medicine, with a consensus EPS loss of $-1.73. The company has not provided specific guidance, leading to uncertainty among investors.

Bull Case

If the company can narrow its losses and provide positive updates on its product pipeline, it could signal a turnaround, attracting investor interest.

Bear Case

Continued larger-than-expected losses could raise concerns about the company's financial health and ability to fund its operations.

Key Metrics to Watch

EPS

-1.73

Earnings per share is a key indicator of profitability, and investors will be looking for any signs of improvement or worsening losses.

Revenue

$0M

Although no revenue is expected this quarter, any revenue generated would signal progress in the company's product development.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS loss be closer to the consensus estimate of $-1.73 or worse?

The market will closely watch the EPS figure as it reflects the company's financial health and operational efficiency.

Is there any revenue generated this quarter?

Any revenue would indicate progress in the company's product development and could positively influence investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a narrower EPS loss this quarter, as recent operational adjustments could lead to improved cost management.

Supporting Evidence

The historical trend shows that the company has occasionally beaten EPS estimates despite a difficult environment.

Options pricing suggests a higher expected move than historical averages, indicating that traders may anticipate a surprise.

Key Risk

If the EPS loss comes in better than $-1.55, it could challenge the current negative sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will provide insights into the company's ability to manage costs and develop its product pipeline.

Bull Confirmed If

An EPS loss of $-1.55 or better would confirm the bull case, suggesting improved financial performance.

Bear Confirmed If

An EPS loss of $-2.07 or worse would confirm the bear case, raising concerns about the company's sustainability.

Pre-Earnings Positioning

Options Market

Implied Move

±8.27%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±8.3% while IRON has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

33.2%

Calls (0)P/C Ratio: 2.50Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 4 of 18 (22%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$841,283.01

12,388 sh

2 insiders

Net

$841,283.01

Net selling

Most Active Insiders· 4 open-market trades

Chief Financial OfficerFranchi Jean M.
$460,834.05

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Disc Medicine beats expectations with a smaller EPS loss, history suggests the stock could rise by around 0.08%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management.

Miss

A larger-than-expected EPS loss could lead to a decline of about 0.79%, reflecting ongoing concerns about the company's financial stability.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product development timelines and potential revenue generation.
2Management's commentary on cost management strategies and operational efficiency.
3Insights into the company's cash runway and funding strategies.
4Any changes in the competitive landscape that could impact the company's market position.